INMB: INmune Bio, Inc. Cash per Share

Regulatory risks and capital deficits force the management of INmune Bio, Inc. (INMB) to frequently raise investment. The current cash per share illustrates the result of this financial policy, where 0.53 captures the current state of the parameter. INmune Bio, Inc. (INMB) is developing an immune reprogramming system through hospital networks, utilizing TNF modulation to combat neuronal degeneration and oncology.
Comprehensive metric breakdowns and analytics for INmune Bio (INMB)

Cash per share determines the portion of liquid assets attributable to a single common share. The trend in cash per share reflects the issuer's ability to sustain operational activities without external borrowing. The calculation is based on the ratio of total cash balances to the number of shares outstanding. For INmune Bio, Inc. (INMB), this reserve guarantees the funding of immunological developments. Sufficient capital will ensure a seamless transition from laboratory research to the mass production of drugs.